1216290-59-3

Upstream product

• 1479-24-9 ethyl 2-fluorobenzoylacetate 
• 223679-79-6 5-(2-fluorobenzoyl)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 1436418-40-4 C₁₈H₁₇FN₂O₃ 
• 393-52-2 2-Fluorobenzoyl chloride 
• 445-29-4 o-fluoro-benzoic acid 

Downstream Products

• 1436418-06-2 N-(3-fluoro-4-(6-methoxy-7-(3-(4-methylpiperidin-1-yl)propoxy)quinolin-4-yloxy)phenyl)-4-oxo-1-p-tolyl-1,4-dihydrocinnoline-3-carboxamide 

Relevant academic research and scientific papers

Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors

A series of novel 4-(2-fluorophenoxy)quinoline derivatives containing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety were designed, synthesized and evaluated for their in vitro biological activities against c-Met kinase and six typical cancer cell lines (A549, H460, HT-29, MKN-45, U87MG and SMMC-7721). All the prepared compounds showed moderate to excellent antiproliferative activity, and the analysis of their structure-activity relationships indicated that 2-chloro or 2-trifluoromethyl substituted phenyl group on the 1-position of cinnoline ring was more favorable for antitumor activity. In this study, a promising compound 33, with a c-Met IC50 value of 0.59 nM, was identified as a multitargeted receptor tyrosine kinase inhibitor.